SCHEMBL2323940

SCHEMBL2323940

Cc1nc(Br)c(C)c(C)c1C

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26608554 0.79 LMNA (0.40) LMNA
SCHEMBL31128382 0.79 LMNA (0.40) LMNA
SCHEMBL77010 0.75 IDO1 (0.35) LMNA
SCHEMBL12266513 0.75 LMNA (0.36) LMNA
SCHEMBL15055584 0.75 SRC (0.38) LMNA
SCHEMBL31300101 0.75 SRC (0.38) LMNA
SCHEMBL27786450 0.75 LMNA (0.32) LMNA
SCHEMBL1173994 0.72 LMNA (0.36) LMNA
SCHEMBL25948998 0.71 LMNA (0.30) LMNA
SCHEMBL3804726 0.71 ERN1 (0.32) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9889139-B2 Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) 2018-02-13 US disclosed
US-20160354352-A1 METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) 2016-12-08 US disclosed
US-8852757-B2 Organic electroluminescence element, lighting device and display device KONICA MINOLTA HOLDINGS, INC. (JP) 2014-10-07 US disclosed
EP-2531492-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES Heptares Therapeutics Limited (GB) 2012-12-12 EP disclosed
WO-2011095625-A1 1,2,4-TRIAZINE-4-AMINE DERIVATIVES HEPTARES THERAPEUTICS LIMITED (GB) 2011-08-11 WO disclosed
US-7976958-B2 phosphorescence; tetrakis[2-(2,2,4,4-tetrafluoro-1,3-henzodioxan-6-yl)pyridine-C.sup.7,N](mu.-dichloro)diiridium(III) CANON KABUSHIKI KAISHA (JP) 2011-07-12 US disclosed
US-20110006670-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT, NEW COMPOUND FOR THE SAME, DISPLAY DEVICE AND LIGHTING DEVICE USING THE SAME KONICA MINOLTA HOLDINGS, INC. (JP) 2011-01-13 US disclosed
US-20100045171-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT, LIGHTING DEVICE AND DISPLAY DEVICE KONICA MINOLTA HOLDINGS, INC. (JP) 2010-02-25 US disclosed
US-7534506-B2 Luminescence device, display apparatus and metal coordination compound CANON KABUSHIKI KAISHA (JP) 2009-05-19 US disclosed
US-20080131730-A1 METAL COMPLEX COMPOUND, ELECTROLUMINESCENT DEVICE AND DISPLAY APPARATUS CANON KABUSHIKI KAISHA (JP) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080131730-A1 METAL COMPLEX COMPOUND, ELECTROLUMINESCENT DEVICE AND DISPLAY APPARATUS L1CAM, EMC1, EMC2 LMNA 3316/4885
US-20110006670-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT, NEW COMPOUND FOR THE SAME, DISPLAY DEVICE AND LIGHTING DEVICE USING THE SAME AOC2, AOC3, CDYL LMNA 3272/4885
US-20160354352-A1 METHOD OF TREATING INFLAMMATORY BOWEL DISEASE COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING A 6-AMINOPYRIDIN-3-OL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT TO A SUBJECT SI, SLC10A2, ALPI LMNA 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.